Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Pressure BioSciences, Inc. (OTCQB:PBIO)CEO Schumacher Outlines Why Continued Record Growth-Sales 2018 Will Continue In A Recent Interview

|Includes: Pressure BioSciences, Inc. (PBIO)
Summary

Newly Redesigned and Improved Flagship Barocycler 2320EXTREME Instrument.

Two Year Crossover Marketing Agreement with ISS.

Acquisition of Barofold.

Additions to Sales Force.

Home

In a recent interview March 8, 2018 Ric Schumacher CEO of Pressure BioSciences, Inc. (NYSE:PBI) layed out the groundwork and game plan for what is expected to be another Record Year in Sales for PBI.

https://upticknewswire.com/wp-content/uploads/2018/03/Uptick-Network-PBIO-Interview-3-8-18.mp3

The new redesigned/improved Barocycler 2320EXTREME is now Completely Computerized. Previously it ran off a Microprocessor hindering it's capacity and performance even though over 300 have been placed with 150 Marquee Clients Worldwide in Major Labs and Universities.

The newest Barocycler 2320EXTREME Instrument now allows for the Segue into many new arenas. It's capable of performing functions such as not only recording necessary data, but printing or downloading that data step by step, on say a Thumb Drive. Previously only Hand Written Notes were afforded as data flowed. Available now is the ability to take this instrument and complete the entire process A - Z from R&D to Quality Control, to a New Drug hitting the marketplace. This will be Key in the Pharmaceutical industry. Existing Clients (some Multi Billion $ Companies) that have been waiting years for this, that owned one, perhaps two old Barocyclers, have already Purchased as many as 4 of the Newer Barocycler Instrument.

PBI is anticipating a Blockbuster year in Sales for the Barocycler 2320EXTREME

Pressure BioSciences, Inc. and ISS, Inc. Announce Two-Year Worldwide Co-Marketing and Distribution Agreement-They Will Cross Sell Each Others Technologies & Instruments.

ISS High Pressure Optical Cell Integrated with PBI Automated High Pressure Instrument: Combination Results in Unique Analytical System with Potential to Significantly Improve and Enhance Launches PBI INTO The Biopharmaceutical Drug Discovery and Development Sectors

We believe that replacing this manual crank pressure generator with the computer controlled HUB 440/880 pressure instruments from PBI could result in the ability to visualize biochemical reactions as they are happening in the pressure cell. The PBI pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide.


Pressure BioSciences, Inc. and ISS, Inc. Announce Two-Year Worldwide Co-Marketing and Distribution Agreement

PBI Acquires Eight New Patents & Assets of Barofold, Inc.

Pressure BioSciences Announces Acquisition of All Assets of BaroFold, Inc.

Increasing the Sales Force is Significant. For Nine Years PBI had One Sales Rep basically working from Home. PBI with one rep working mainly from home grew from a few sales per year company, to a Two Million Dollar per year company. The company brought on four new sales reps, dividing the country into four territories. With the Addition of Four New Sales Reps, out of the office making sales calls to businesses, it is expected to correlate to Four Times the Sales.

As the interview winds down the subject of the company being Undervalued and the share price being low for a $4,000,000 Plus Market Cap was discussed. What we believe was year end selling, and impatience, dropped the price down to a low of $2.76, it rose back up to $3.30 where some took advantage. It currently sits around $4.80 per share or a recent bounce up of 45%.

We think (PBIO) is a Long Play with Short Term Gain Potential as proven recently.

A Third Party Source States (PBIO) is a Buy - Analysts have a Target of $10.00

Don't Miss out on this DITR

Third Party Publication:  The Quiet Investor Issues March 2018 Publication Featuring Pressure BioSciences, Inc. (OTCQB:PBIO) - Small cap Solutions, LLC 

Investor Presentation: https://d1io3yog0oux5.cloudfront.net/_16dc02d18d3b045d7a7a63b78ea31469/pressurebiosciences/db/399/3062/pdf/Jan+2018+Investor+Presentation.pdf

Robert E. Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

Twitter: RobKreh@scs,llc@RobKreh

Subscribe @ smallcapsolutions.com

(OTCQB:PBIO) Disclaimer:

You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Pressure BioSciences, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at otcmarkrts.com yahoofinance.com - Small Cap Solutions, LLC has received ($3,000.00) cash from Value Quest, Inc. for investor relations services rendered for Pressure BioSciences, Inc. Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(S) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer(S) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.